Annovis Bio (NYSE:ANVS) Reports Narrower Q2 2025 Loss, Advances Alzheimer's and Parkinson's Trials

Annovis Bio Inc. (NYSE:ANVS) reported its second-quarter 2025 financial results, posting a net loss per share of $0.32, which was narrower than the analyst consensus estimate of a $0.41 loss. The company, which focuses on developing treatments for neurodegenerative diseases such as Alzheimer’s (AD) and Parkinson’s (PD), reported no revenue for the quarter, in line with expectations.

Earnings and Market Reaction

• EPS Performance: The reported loss of $0.32 per share was better than the anticipated $0.41 loss, reflecting improved cost management. Research and development expenses declined to $5.2 million from $5.8 million in the prior-year quarter, while general and administrative expenses fell to $1.1 million from $2.0 million.
• Revenue: As expected, Annovis reported no revenue, given its clinical-stage status. The company remains focused on advancing its lead drug candidate, buntanetap, through late-stage trials.
• Cash Position: Annovis ended the quarter with $17.1 million in cash and cash equivalents, up from $10.6 million at the end of 2024, providing a runway to continue its clinical programs.

The stock saw a slight decline in after-hours trading, dipping approximately 0.36%, suggesting a muted reaction to the earnings beat. Over the past month, shares have risen by about 3.4%, indicating cautious optimism among investors as the company progresses its clinical trials.

Key Updates from the Press Release

Annovis highlighted several milestones in its Q2 update:

• Clinical Progress: Enrollment in the pivotal Phase 3 trial for early Alzheimer’s disease (NCT06709014) continues, with 76 U.S. sites secured and 46 actively enrolling patients. Over 400 patients have been screened, with 38 already receiving treatment.
• Intellectual Property: The company completed the transfer of all patent families to its lead drug candidate, crystal buntanetap, strengthening its global IP protection.
• Scientific Presentations: Annovis presented four scientific posters at the Alzheimer’s Association International Conference (AAIC) 2025, reinforcing the potential of buntanetap in neurodegenerative diseases.

Looking Ahead

Analysts estimate a Q3 2025 loss of $0.33 per share, with no revenue expected. For the full year, the consensus projects a loss of $1.63 per share. While Annovis has no near-term revenue prospects, investor focus remains on clinical trial progress and potential regulatory milestones.

For more detailed earnings estimates and historical performance, visit Annovis Bio’s earnings page.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors should conduct their own research before making any financial decisions.